131 related articles for article (PubMed ID: 36050598)
1. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
Youn JC; Kim D; Kim KA; Kim JJ; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
Am J Transplant; 2022 Dec; 22(12):2942-2950. PubMed ID: 36050598
[TBL] [Abstract][Full Text] [Related]
2. Association of Pretransplant Skin Cancer With Posttransplant Malignancy, Graft Failure and Death in Kidney Transplant Recipients.
Kang W; Sampaio MS; Huang E; Bunnapradist S
Transplantation; 2017 Jun; 101(6):1303-1309. PubMed ID: 27336396
[TBL] [Abstract][Full Text] [Related]
3. Pediatric heart transplantation: 23-year single-center experience.
Huebler M; Schubert S; Lehmkuhl HB; Weng Y; Miera O; Alexi-Meskishvili V; Berger F; Hetzer R
Eur J Cardiothorac Surg; 2011 May; 39(5):e83-9. PubMed ID: 21354807
[TBL] [Abstract][Full Text] [Related]
4. Characteristics, outcomes, and predictors of
Youn JC; Kim D; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
Front Cardiovasc Med; 2022; 9():939275. PubMed ID: 36003907
[TBL] [Abstract][Full Text] [Related]
5. De novo malignancy in heart transplant recipients: A single center experience in Japan.
Kimura Y; Yanase M; Mochizuki H; Iwasaki K; Toda K; Matsuda S; Takenaka H; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Ikura MM; Wada K; Matsumoto Y; Seguchi O; Fukushima S; Fujita T; Kobayashi J; Fukushima N
J Cardiol; 2019 Mar; 73(3):255-261. PubMed ID: 30587457
[TBL] [Abstract][Full Text] [Related]
6. De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients.
Solé-González E; Mirabet S; Brossa V; López-López L; Rivas-Lasarte M; Capellades-Olivella H; Ginel-Iglesias AJ; Martorell-Pons J; Roig E
Transplant Proc; 2016 Nov; 48(9):3030-3032. PubMed ID: 27932139
[TBL] [Abstract][Full Text] [Related]
7. Early aspirin use and the development of cardiac allograft vasculopathy in pediatric heart transplant recipients: A pediatric heart transplant society analysis.
D'Addese L; Cantor RS; Koehl D; Reardon L; Ameduri R; Bock M; Morrison A; White S; Wisotzkey B; Kirklin JK; Godown J
J Heart Lung Transplant; 2023 Jan; 42(1):115-123. PubMed ID: 36328858
[TBL] [Abstract][Full Text] [Related]
8. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation.
Nath DS; Angaswamy N; Basha HI; Phelan D; Moazami N; Ewald GA; Mohanakumar T
Hum Immunol; 2010 Dec; 71(12):1191-6. PubMed ID: 20868717
[TBL] [Abstract][Full Text] [Related]
9. Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients-a SCHEDULE trial substudy.
Nelson LM; Andreassen AK; Arora S; Andersson B; Gude E; Eiskjaer H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
Transpl Int; 2020 May; 33(5):517-528. PubMed ID: 31958178
[TBL] [Abstract][Full Text] [Related]
10. Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation.
Vaughn GR; Jorgensen NW; Law YM; Albers EL; Hong BJ; Friedland-Little JM; Kemna MS
Pediatr Transplant; 2018 Feb; 22(1):. PubMed ID: 29222866
[TBL] [Abstract][Full Text] [Related]
11. Left ventricular global longitudinal strain predicts major adverse cardiac events and all-cause mortality in heart transplant patients.
Clemmensen TS; Eiskjær H; Løgstrup BB; Ilkjær LB; Poulsen SH
J Heart Lung Transplant; 2017 May; 36(5):567-576. PubMed ID: 28089194
[TBL] [Abstract][Full Text] [Related]
12. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
13. Heart transplantation: 25 years' single-centre experience.
Bruschi G; Colombo T; Oliva F; Botta L; Morici N; Cannata A; Vittori C; Turazza F; Garascia A; Pedrazzini G; Frigerio M; Martinelli L
J Cardiovasc Med (Hagerstown); 2013 Sep; 14(9):637-47. PubMed ID: 23340045
[TBL] [Abstract][Full Text] [Related]
14. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy.
Nath DS; Ilias Basha H; Tiriveedhi V; Alur C; Phelan D; Ewald GA; Moazami N; Mohanakumar T
J Heart Lung Transplant; 2010 Nov; 29(11):1277-85. PubMed ID: 20615726
[TBL] [Abstract][Full Text] [Related]
15. Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients.
Grupper A; AbouEzzeddine OF; Maleszewski JJ; Grupper A; Geske JR; Kremers WK; Kushwaha SS; Pereira NL
Clin Transplant; 2018 Sep; 32(9):e13349. PubMed ID: 29998506
[TBL] [Abstract][Full Text] [Related]
16. Pediatric recipient survival beyond 15 post-heart transplant years: a single-center experience.
Copeland H; Razzouk A; Chinnock R; Deming D; Hasaniya N; Bailey L
Ann Thorac Surg; 2014 Dec; 98(6):2145-50; discussion 2150-1. PubMed ID: 25443019
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of third heart transplants in pediatric and young adult patients: analysis of the United Network for Organ Sharing database.
Friedland-Little JM; Gajarski RJ; Yu S; Donohue JE; Zamberlan MC; Schumacher KR
J Heart Lung Transplant; 2014 Sep; 33(9):917-23. PubMed ID: 24861821
[TBL] [Abstract][Full Text] [Related]
18. Sex Related Differences in the Risk of Antibody-Mediated Rejection and Subsequent Allograft Vasculopathy Post-Heart Transplantation: A Single-Center Experience.
Grupper A; Nestorovic EM; Daly RC; Milic NM; Joyce LD; Stulak JM; Joyce DL; Edwards BS; Pereira NL; Kushwaha SS
Transplant Direct; 2016 Oct; 2(10):e106. PubMed ID: 27795988
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cardiac allograft vasculopathy in heart and heart-lung transplantations: a 15-year retrospective study.
Guihaire J; Mercier O; Flécher E; Aymami M; Fattal S; Chabanne C; Leroy Ladurie F; Lelong B; Cerrina J; Langanay T; Mussot S; Fabre D; De Latour B; Corbineau H; Verhoye JP; Dartevelle P; Leguerrier A; Fadel E
J Heart Lung Transplant; 2014 Jun; 33(6):636-43. PubMed ID: 24630860
[TBL] [Abstract][Full Text] [Related]
20. mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy.
Kreienbaum H; Stiller B; Kubicki R; Bobrowski A; Kroll J; Fleck T
Pediatr Transplant; 2024 Mar; 28(2):e14698. PubMed ID: 38433342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
